title: Localization of rate-limiting defect for glucose disposal in skeletal muscle of insulin-resistant type I diabetic patients.
abstract: We searched for metabolic crossover points in muscle glucose metabolite profiles during maintenance of matched glucose fluxes across forearm muscle in insulin-resistant type I (insulin-dependent) diabetic patients and nondiabetic subjects. To classify subjects as insulin sensitive or insulin resistant, whole-body and forearm glucose disposal, oxidative and nonoxidative glucose disposal (indirect calorimetry), and glycogen synthesis (muscle glycogen content in needle biopsies) were measured under euglycemic conditions at two insulin concentrations. Whole-body and forearm muscle glucose disposal were significantly reduced in diabetic patients compared with control subjects. The reduction in total glucose disposal was due to similar relative reductions in oxidative and nonoxidative glucose disposal, pointing toward rate limitation early in glucose metabolism. The defect in nonoxidative glucose disposal was at least partly due to a defect in muscle glycogen synthesis, because muscle glycogen content failed to increase in response to an increase in the plasma insulin concentration in the diabetic patients. The most-insulin-resistant type 1 diabetic patients were restudied under conditions where, by glucose mass action, whole-body glucose disposal was forced to be similar to that in the control subjects. Matching glucose fluxes in the two groups resulted in similar rates of forearm and whole-body oxidative and nonoxidative glucose disposal and muscle glycogen synthesis, but it did not result in accumulation of free intracellular glucose, glucose-6-phosphate, glucose-1-phosphate, fructose-6-phosphate, or lactate in muscle. These data imply that the rate-limiting defect for glucose disposal in skeletal muscle of type I diabetic patients is at the level of glucose transport.
authors.affiliation: Second Department of Medicine, University of Helsinki, Finland.
authors.forename: H
authors.initials: H
authors.lastname: Yki-Järvinen
authors.forename: K
authors.initials: K
authors.lastname: Sahlin
authors.forename: J M
authors.initials: JM
authors.lastname: Ren
authors.forename: V A
authors.initials: VA
authors.lastname: Koivisto
mesh_terms: D000328:Adult; D001692:Biological Transport; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D005947:Glucose / Q000378:metabolism* / Q000493:pharmacokinetics; D006003:Glycogen / Q000097:blood; D006006:Glycogen Synthase / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D008657:Metabolic Clearance Rate; D009132:Muscles / Q000201:enzymology / Q000378:metabolism*; D010084:Oxidation-Reduction
chemical_list: D007328:Insulin; D006003:Glycogen; D006006:Glycogen Synthase; D005947:Glucose